For Alkermes PLC, the value proposition lies in using its knowledge in drug delivery and formulations to make a new slate of pipeline candidates – in particular, drugs that rely on proven blockbusters but provide further benefits to patient experiences. The Dublin and Waltham, Mass.-based biotech announced at an R&D day on July 17 the addition to its pipeline of three new drug candidates, which it believes it can effectively differentiate in the marketplace.
Alkermes expects to have three new drugs in the clinic by mid-2014, fleshing out its pipeline to include a total...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?